PATENT CLAIM ANALYSIS

Application Number: 16225894
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "618000"]

Abstract:
The present application relates to compounds according to (Formula IA) or (Formula IB): or a pharmaceutically acceptable salt thereof. The compounds can be used as inhibitors of RORγ and are useful for the treatment of RORγ mediated diseases.

Claim (Index 16):
A method of therapeutically treating at least one condition selected from the group consisting of ROR-\u03b3 mediated autoimmune diseases, ROR-\u03b3 mediated inflammatory diseases and ROR-\u03b3 mediated infectious diseases, comprising administering an effective amount of a compound having the absolute configuration corresponding to Formula (IA), or a pharmaceutically acceptable salt thereof, to a person in need of a therapeutic treatment, wherein the compound of Formula (IA) is 2-{4-[(cyclopropylmethyl)sulfonyl]phenyl}-N-{4-[(1R)-1-(difluoromethyl)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}acetamide:

Metadata:
- Claim Count in Document: 38.0
- Percentile: 98.0
- Lexical Diversity: 1.28571
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15829226', '15102098', '15579164', '15578997', '15579111']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7447137893245254
- 35 USC 102 Novelty (BERT): 0.5755542734647807
- Combined Prediction Score: 0.727797837738551
- Mean Citation Score: 339.039382
- Max Citation Score: 476.3625
- Similarity Product: 372.5622982442379

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test